Failure of valacyclovir for herpes zoster in a moderately immunocompromised HIV-infected patient

AIDS Patient Care and STDs

Volumn 18, Issue 5, 2004, Pages 255-257

  Breton, Guillaume ^a   Bouldouyre, M A ^a   Gervais, A ^a   Duval, X ^a   Longuet, P ^a   Leport, C ^a   Vilde J L ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; VALACICLOVIR;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MALE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ACYCLOVIR; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; ELECTROMYOGRAPHY; HERPES ZOSTER; HUMANS; IMMUNOCOMPROMISED HOST; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PATIENT SELECTION; RADICULOPATHY; TREATMENT FAILURE; VALINE; VIRAL LOAD;

EID: 2642587483     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729104323075990     Document Type: Article

References (12)

1. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-1156.
2. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with HIV. Clin Infect Dis 1995;21:370-375.
3. Snoeck R, Andrei G, De Clercq E. Current pharmacological approaches to the therapy of varicella zoster virus infections. A guide to treatment. Drugs 1999;57:187-206.
4. Cohen JI, Brunell PA, Strauss SE, Krause PR. Recent advances in varicella zoster virus infection. NIH Conference. Ann Intern Med 1999;130:922-932.
5. Strauss SE, Ostrove JM, Inchaupsé G, Felser JM, Freifeld A, Croen KD. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. NIH Conference. Ann Intern Med 1988;108: 221-237.
6. de la Blanchardiere A, Rozemberg F, Caumes E, et al. Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand J Infect Dis 2000;32:263-269.
7. Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: Results of foscarnet therapy. Clin Infect Dis 1998;27:1525-1527.
8. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-1553.
9. Balfour HH, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983;308:1448-1453.
10. Wagstaff AJ, Faulds D, Goa KL. Acyclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:153-205.
11. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drugs valacyclovir after escalading single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
12. Veenstra J, van Praag RM, Krol A, et al. Complications of VZV reactivations in HIV-infected homosexual men. AIDS 1996;10:393-399.